Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist (CAS 2023788-19-2) at 99.3% HPLC-verified purity. Acts on two incretin receptors simultaneously for synergistic metabolic pathway research.
Tirzepatide — Research Summary
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, representing a new class of investigational compounds. It acts on two distinct incretin receptors simultaneously, offering researchers a unique tool for studying synergistic metabolic pathways. Current research explores its effects on body weight regulation, glycemic control, and lipid metabolism. Tirzepatide is one of the most studied new peptide compounds in metabolic research. For research use only.
Researchers Also Study
For research use only. Not for human or animal consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used solely for lawful laboratory research.